0001193125-22-008657.txt : 20220113 0001193125-22-008657.hdr.sgml : 20220113 20220113160403 ACCESSION NUMBER: 0001193125-22-008657 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220113 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20220113 DATE AS OF CHANGE: 20220113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 22529118 BUSINESS ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 51285113796 MAIL ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 8-K 1 d287345d8k.htm 8-K 8-K
Savara Inc false 0001160308 0001160308 2022-01-13 2022-01-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 13, 2022

 

 

SAVARA INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-32157   84-1318182

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

6836 Bee Cave Road, Building III, Suite 201

Austin, TX 78746

(Address of principal executive offices, including zip code)

(512) 614-1848

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   SVRA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 13, 2022, upon the recommendation of the Compensation Committee of the Board of Directors (the “Board”) of Savara Inc. (“Savara”), the Board approved the target bonus amounts for Savara’s executive officers for the year ended December 31, 2022. The approved target bonus amounts for each of the Company’s executive officers for the year ended December 31, 2022 are as follows:

 

Executive Officer

  

Title

   Target
Bonus
     % of Base
Salary
 

Matthew Pauls

   Chief Executive Officer    $ 290,000        50

Badrul Chowdhury

   Chief Medical Officer    $ 219,544        40

Dave Lowrance

   Chief Financial Officer    $ 166,690        40

Actual bonus amounts paid to the executive officers may be more or less than the target bonus amounts. The total bonus payment amounts will be based on the achievement of certain performance goals, and the Board has the discretion to award bonus amounts that differ for attainment of performance goals that fall above or below such goals. For Mr. Pauls, the achievement of corporate performance measures will represent 100% of his target bonus award. For each of Dr. Chowdhury and Mr. Lowrance, the achievement of corporate performance measures will represent 75% of the target bonus award and individual performance measures will represent 25% of the target bonus award.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 13, 2022

    SAVARA INC.
a Delaware corporation
    By:  

/s/ Dave Lowrance

     

Dave Lowrance

Chief Financial Officer

EX-101.SCH 2 svra-20220113.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 svra-20220113_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 svra-20220113_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Jan. 13, 2022
Cover [Abstract]  
Entity Registrant Name Savara Inc
Amendment Flag false
Entity Central Index Key 0001160308
Document Type 8-K
Document Period End Date Jan. 13, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-32157
Entity Tax Identification Number 84-1318182
Entity Address, Address Line One 6836 Bee Cave Road
Entity Address, Address Line Two Building III
Entity Address, Address Line Three Suite 201
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78746
City Area Code (512)
Local Phone Number 614-1848
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol SVRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d287345d8k_htm.xml IDEA: XBRL DOCUMENT 0001160308 2022-01-13 2022-01-13 Savara Inc false 0001160308 8-K 2022-01-13 DE 001-32157 84-1318182 6836 Bee Cave Road Building III Suite 201 Austin TX 78746 (512) 614-1848 false false false false Common Stock, par value $0.001 per share SVRA NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d287345d8k.htm svra-20220113.xsd svra-20220113_lab.xml svra-20220113_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d287345d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d287345d8k.htm" ] }, "labelLink": { "local": [ "svra-20220113_lab.xml" ] }, "presentationLink": { "local": [ "svra-20220113_pre.xml" ] }, "schema": { "local": [ "svra-20220113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "svra", "nsuri": "http://www.savarapharma.com/20220113", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d287345d8k.htm", "contextRef": "duration_2022-01-13_to_2022-01-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d287345d8k.htm", "contextRef": "duration_2022-01-13_to_2022-01-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.savarapharma.com//20220113/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001193125-22-008657-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-008657-xbrl.zip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end